Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations

Intern Med. 2006;45(21):1213-5. doi: 10.2169/internalmedicine.45.1816. Epub 2006 Dec 1.

Abstract

We report a patient whose cryoglobulinemic vasculitis recurred due to reactivation of lamivudine-resistant HBV. Our patient with hepatitis B-related cryoglobulinemic vasculitis was administered lamivudine. Her vasculitis regressed, ALT normalized, HBV-DNA became negative. Under lamivudine therapy, her cryoglobulinemic cutaneous vasculitis recurred. ALT increased significantly; it was found that tyrosine-methionine-aspartate-aspartate (YMDD) motif in the DNA polymerase gene had been replaced by YIDD. Adefovir was added to lamivudine. During follow-up, her purpura disappeared, ALT normalized, HBV-DNA became negative. Our patient is the first whose cryoglobulinemic vasculitis recurred under lamivudine, who had a HBV virologic breakthrough with YMDD mutation, and was successfully treated with adefovir.

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Amino Acid Motifs / genetics
  • Aspartic Acid / genetics
  • Cryoglobulinemia / diagnosis
  • Cryoglobulinemia / drug therapy
  • Cryoglobulinemia / genetics*
  • Female
  • Hepatitis B / diagnosis
  • Hepatitis B / drug therapy
  • Hepatitis B / genetics*
  • Hepatitis B virus / genetics
  • Humans
  • Lamivudine / therapeutic use*
  • Methionine / genetics
  • Middle Aged
  • Mutation*
  • Organophosphonates / therapeutic use*
  • Recurrence
  • Tyrosine / genetics
  • Vasculitis / diagnosis
  • Vasculitis / drug therapy
  • Vasculitis / genetics*

Substances

  • Organophosphonates
  • Lamivudine
  • Aspartic Acid
  • Tyrosine
  • adefovir
  • Methionine
  • Adenine